Harmony Biosciences (HRMY) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary

Business overview and pipeline

• Profitable, self-funding biotech with four years of profitability and a growing core franchise in narcolepsy.

• Pipeline includes three orphan rare CNS franchises, eight assets across 13 development programs, with four in phase III and up to six by year-end.

• Late-stage pipeline could deliver one to two new product or indication launches annually over the next three to four years.

Commercial performance and growth outlook

• Achieved $185 million in Q1 sales, up 20%, with guidance of $820–$860 million for the year and a target of 8,000 patients by year-end.

• Long-term opportunity to reach 9,000 patients and $1 billion in sales, tapping into an 80,000-patient market.

• Growth driven by expanding prescriber base and differentiated product profile as the only non-scheduled narcolepsy treatment.

Leadership and strategy

• New Chief Commercial Officer brings 25 years of experience, no major changes planned, but will seek growth levers.

• Focus remains on building from a strong commercial foundation and leveraging analytics for life cycle management.